CytoPherx Raises $34 Million to Move Into US Clinical Trials - MarketWatch (press release) PDF Print
MarketWatch (press release)
"Mortality rates of patients experiencing acute kidney injury combined with multi-organ failure and/or severe sepsis and requiring Continuous Renal Replacement Therapy (CRRT) are often greater than 50%," said Jim Danehy, President and CEO of CytoPherx.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.